Liposomal-lupane system as alternative chemotherapy against cutaneous leishmaniasis: macrophage as target cell.
Leishmania amazonensis causes human diseases that range from self-healing to diffusion cutaneous lesions. The chemotherapy of leishmaniasis requires long-term treatment and has been based on the use of pentavalent antimonials. Liposomes have been used as antileishmanial drug carries and have adjuvant activity in vaccines against several microorganisms, representing an important option to the development of new therapeutics for the disease. In this study, we developed a liposomal formulation containing lupane [3β,6β,16β-trihydroxylup-20(29)-ene], isolated from fruits of Combretum leprosum with pharmacological properties as antinociceptive, anti-inflammatory, antiulcerogenic and antileishmanial activities. The aim of the present study was to evaluate the efficacy of liposomal-lupane in L. amazonensis-infection model. Liposomes were prepared by the extrusion method with DPPC, DPPS and cholesterol at 5:1:4 weight ratio. The lupane (2 mg/mL) was added to the lipid mixture, solubilized in chloroform and dried under nitrogen flow. The activity of liposomal-lupane was conducted in vitro with mouse peritoneal infected macrophages. Furthermore, mice were infected in the right hind footpad with 10(5) stationary growth phase of L. amazonensis promastigotes. After 6 weeks, animals were treated with liposomal-lupane for 15 days by intraperitoneal injection. The evolution of disease was monitored weekly by measuring footpad thickness with a caliper. Three days after the treatment, peritoneal macrophages were collected, plated and production of the cytokines IL-10 and IL-12 was evaluated in supernatants of the cultures after 24 h. The results indicate that the liposomal system containing lupane achieved here is a promising tool to confer antileishmanial activity to infected macrophages.
Fundação Oswaldo Cruz (FIOCRUZ-RONDÔNIA), Porto Velho, RO, Brazil. Electronic address: neuzabiguinati@gmail.com.
Neuza B
NB
Barros
Vanessa
V
Migliaccio
Valdir A
VA
Facundo
Pietro
P
Ciancaglini
Rodrigo G
RG
Stábeli
Roberto
R
Nicolete
Izaltina
I
Silva-Jardim
D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage*; D029765:Combretum / Q000737:chemistry; D004195:Disease Models, Animal; D016753:Interleukin-10 / Q000378:metabolism; D018664:Interleukin-12 / Q000378:metabolism; D007894:Leishmania mexicana / Q000187:drug effects* / Q000254:growth & development; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy* / Q000473:pathology; D008081:Liposomes; D017737:Macrophages, Peritoneal / Q000187:drug effects / Q000276:immunology / Q000469:parasitology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010419:Pentamidine / Q000008:administration & dosage; D010936:Plant Extracts / Q000008:administration & dosage; D014315:Triterpenes / Q000008:administration & dosage*; D053978:Pentacyclic Triterpenes
D000981:Antiprotozoal Agents; D016753:Interleukin-10; D018664:Interleukin-12; D008081:Liposomes; D010419:Pentamidine; D010936:Plant Extracts; D014315:Triterpenes; C480546:lupane; D053978:Pentacyclic Triterpenes
Leishmania amazonensis; Liposomes; Lupane; Macrophages